Edition:
United States

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

25.24USD
11:33am EDT
Change (% chg)

$0.29 (+1.16%)
Prev Close
$24.95
Open
$25.00
Day's High
$25.40
Day's Low
$25.00
Volume
2,790
Avg. Vol
54,568
52-wk High
$35.52
52-wk Low
$16.98

Chart for

About

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocyt... (more)

Overall

Beta: --
Market Cap(Mil.): $721.83
Shares Outstanding(Mil.): 28.15
Dividend: --
Yield (%): --

Financials

  DOVA.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -1.19 -- --
ROI: -73.40 -0.71 13.13
ROE: -88.13 -2.76 14.96

BRIEF-Dova Pharmaceuticals Announces Proposed Offering Of Common Stock

* DOVA PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

Feb 20 2018

BRIEF-Dova Pharma Files For Offering Of Up To 2.5 Mln Shares

* DOVA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 2.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2FgTI9o) Further company coverage:

Feb 20 2018

BRIEF-Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​

* DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

Feb 15 2018

BRIEF-Dova Pharmaceuticals Announces Appointment Of Mark W. Hahn As Chief Financial Officer

* DOVA PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARK W. HAHN AS CHIEF FINANCIAL OFFICER

Jan 30 2018

BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018

* DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

Jan 03 2018

BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review

* DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW

Nov 27 2017

BRIEF-Dova Pharmaceuticals reports third quarter results

* Dova Pharmaceuticals reports third quarter 2017 operating and financial results

Nov 09 2017

Earnings vs. Estimates